Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2017-04-25 Report Publication Anno…
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Document availability communications / Methods of making financial reports or updated prospectuses available
Report Publication Announcement Classification · 1% confidence The document is titled "*Publication of 2016 Registration Document*" and explicitly states that the company announced the publication of its 2016 Registration Document. It mentions that this document includes the annual financial report, corporate governance report, and auditors' reports. Crucially, the document itself is a short press release announcing the availability of this larger report, rather than the report content itself. According to Rule 2 (The "MENU VS MEAL" Rule), a short announcement stating that a report has been published or is available points towards a Report Publication Announcement (RPA). The document is short (4045 chars) and serves only to inform stakeholders that the Registration Document is now available.
2017-04-25 English
Communiqués de mise à disposition de documents / Modalités de mise à disposition document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is a press release dated April 25, 2017, announcing the 'publication de son Document de Référence 2016' (publication of its 2016 Reference Document). It explicitly states that the document was filed with the AMF (Autorité des Marchés Financiers) and is available for consultation. The text mentions that the Reference Document integrates the annual financial report, governance report, and auditor reports. Since the document itself is an announcement about the availability of a major regulatory filing (the Reference Document, which contains the annual report elements), and given its short length (4693 characters) and focus on informing the public where to find the main report, it fits the definition of a Report Publication Announcement (RPA). It is not the full Annual Report (10-K) or the Interim Report (IR), but the announcement of their availability within the Reference Document structure.
2017-04-25 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated April 24, 2017, announcing a partnership between Clinigen and Onxeo to launch a Managed Access (Named Patient) program for the drug belinostat in Europe for patients with Peripheral T-Cell Lymphoma (PTCL). This type of announcement, detailing a specific business arrangement, partnership, or operational update regarding drug access outside of standard financial reporting periods (like 10-K or IR), does not fit neatly into the core financial filing categories (10-K, IR, ER, DIV, etc.). It is a general corporate announcement concerning operations and strategy. Since it is not a formal regulatory filing like a Director's Dealing (DIRS) or a Major Shareholding Notification (MRQ), and it is not a transcript (CT) or a formal presentation (IP), the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it serves as a public disclosure of a significant operational event.
2017-04-24 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document announces a partnership between Clinigen and Onxeo to initiate a Managed Access Programme (MAP) for the drug belinostat in Europe for patients with PTCL. This is a specific operational announcement regarding drug access and commercial strategy, not a standard periodic financial report (like 10-K, IR, ER, or MRQ). It details a business agreement and access mechanism. While it relates to business operations, it doesn't fit neatly into M&A (TAR), Capital changes (CAP/SHA), or Director changes (MANG). It is a specific business development/access announcement. Given the options, this type of announcement, which details a specific operational agreement for drug access outside of standard regulatory financial reporting, is best categorized as a general Regulatory Filing (RNS) or potentially a specific business update. Since it is a press release detailing a specific business arrangement (Managed Access Programme launch), and there is no specific code for 'Business Development' or 'Partnership Announcement', RNS (Regulatory Filings / General Announcement) serves as the most appropriate fallback for non-standard, material corporate news that isn't explicitly covered by other codes.
2017-04-24 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated April 20, 2017, announcing that the company Onxeo has received the 'Tech 40 Label' from EnterNext and is joining the corresponding index. This is a general corporate announcement regarding recognition and status, not a mandatory financial filing like a 10-K, IR, or ER. It does not fit the specific definitions for AGM-R, AR, MANG, CT, CAP, DVA, DLST, DIRS, SR, FS, CGR, IRAT, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, SHA, or POS. It is a general regulatory/corporate announcement that doesn't fit the other specific categories, making 'Regulatory Filings' (RNS) the most appropriate fallback category for miscellaneous corporate news releases.
2017-04-20 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is titled as a press release announcing that Onxeo received the EnterNext Tech 40 Label and was admitted to the 'Tech 40' index. It contains company information, a disclaimer, and contact details typical of a formal announcement. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI). Since it is a general, non-specific regulatory announcement or press release that doesn't fit the other defined categories (like AGM, M&A, Capital Change, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length (4120 chars) is short, but it is the primary content, not an announcement *about* another report, so the RPA rule does not strictly apply here, although RNS is the best fit for general corporate news releases.
2017-04-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.